The von Hippel Lindau (VHL) protein is a key executor of the cellular hypoxic response that is compromised in preeclampsia, a serious disorder complicating 5% to 7% of pregnancies. To date, the mechanisms controlling VHL gene expression in the human placenta remain elusive.
JMJD6 and its histone targets with the VHL promoter. Findings in preeclampsia were corroborated in a murine model of pharmacological hypoxia using FG-4592. Placentae from FG-4592-treated mice exhibited reduced VHL levels, accompanied by placental morphological alterations and reduced pup weights. Notably, Fe 2+ supplementation rescued JMJD6 histone demethylase activity in histone from E-PE and FG-4592-treated mice.
Conclusions: Our study uncovers epigenetic regulation of VHL and its functional consequences for altered oxygen and iron homeostasis in preeclampsia. (J Clin Endocrinol Metab 103: 1545-1557, 2018) W idely recognized for its roles in the cellular oxygensensing pathway (1) and the inheritance of a rare cancer syndrome (2) , the multifaceted von Hippel Lindau (VHL) tumor suppressor protein is also critically required for proper placental development. Evidence for this comes from the Vhl 2/2 mouse that exhibits embryonic lethality primarily due to failure of placental vasculogenesis, resulting in hemorrhage and necrotic cell death (3) . Canonically, in response to oxygen (O 2 )-dependent proline hydroxylation of hypoxia-inducible factor 1a (HIF1A), VHL forms a ubiquitin ligase complex with Cullin 2 and Elongins B and C, targeting HIF1A for polyubiquitination and proteasomal degradation (1) . Thus, by virtue of fine-tuning the HIF1-dependent transcriptional response, VHL is a critical regulator of the global hypoxic gene expression program. In the human placenta, VHL protein (pVHL) is abundantly expressed, exhibits a unique developmental profile, and regulates HIF1A levels in a manner that is dependent on physiological changes in oxygen tension experience by the developing placenta (4) . Despite the wealth of knowledge on the multitasking functions of VHL, little is known about its upstream regulators. Most work has focused on VHL genetic and epigenetic inactivation in renal cell carcinoma (RCC), a highly prevalent type of kidney cancer. Particularly, studies have reported both somatic mutations (including single-nucleotide polymorphims, frameshift deletions/insertions, and missense and nonsense mutations) as well as hypermethylation of CpG islands in VHL in a subtype of RCC tumors affecting renal clear cells (ccRCCs) (5) .
Recently, we have identified a novel oxygen sensor, the Jumonji C (JmjC) domain containing protein 6 (JMJD6), as a key regulator of HIF1A signaling (6) . JMJD6 belongs to a conserved family of the JmjC domain [the primary site of substrate binding and execution of catalytic activity (7) ] containing proteins that function as protein hydroxylases and histone demethylases, requiring molecular O 2 , a-keto-glutarate, and ferrous iron (Fe 2+ ) to execute their enzymatic functions. The biochemical reaction yields formaldehyde, succinate, and carbon dioxide in addition to the demethylated substrate (8) . Although most of the JmjC domain containing proteins catalyze histone lysine demethylation, a unique attribute of JMJD6 is its ability to preferentially demethylate histone arginine marks (9) , with no evidence of histone lysine demethylase activity in vitro or in vivo (10). Although controversial, there is compelling evidence that JMJD6 demethylates dimethylated histone 3 at arginine 2 (H3R2me2s) and dimethylated histone 4 at arginine 3 (H4R3me2s) and can influence gene expression in a locus-specific manner (9, 11, 12) .
Despite the recent advances in elucidating JMJD6 demethylase function, little is known about its epigenetic targets. We have recently described JMJD6 expression and function in the human placenta and showed that it is significantly upregulated in preeclampsia (PE) (6), a placental pathology characterized by maternal hypertension, proteinuria, and end-organ damage (13) . It is estimated that preeclampsia affects between 5% and 8% of all pregnancies and often involves a multitude of fetal and maternal complications (14) . PE is a spectrum disorder and is further classified as early-onset PE (E-PE) and late-onset PE (L-PE) based on etiology, risk factors, clinical features, and feto-maternal outcomes (13, 15) . At the molecular level, E-PE is defined by chronic hypoxia/oxidative stress, disrupted oxygen sensing, and aberrant HIF1A signaling (16, 17) . In the current study, we sought to examine whether JMJD6 is functional as a histone demethylase and, if so, whether VHL is an epigenetic target of JMJD6 in the human placenta in physiological and pathological conditions.
Materials and Methods

Mouse strains
All animal procedures were in accordance with the Ethics Guidelines established by the Canadian Council of Animal Care. The study was approved by the Animal Care Review Committee of the Hospital for Sick Children (AUP 31296). CD1 wild-type (WT) mice (strain code: 022) were obtained from Charles River (St. Constant, Quebec, Canada). Healthy, pregnant, female mice were randomly assigned to experimental or control groups. Pregnant females were injected daily with FG-4592 (0.5 mg/kg body weight) (No. 15294; Cayman Chemical, Ann Arbor, MI), from E7.5 to E13.5, at which time placentae were harvested. Control mice were injected with an equivalent volume of dimethyl sulfoxide (DMSO).
Placental tissue and sera collection
Human placental tissue and sera were collected by the Research Centre for Women's and Infants' Health Biobank and by the O.I.R.M. Sant' Anna Hospital, University of Turin, Italy, following written, informed consent from participants. Procedures were conducted according to the Ethics Guidelines outlined by the Mount Sinai Hospital Research Ethics Board (REB approval 11-0287-E) and the World Medical Association Declaration of Helsinki. Placentae were obtained from pregnancies complicated by E-PE (n = 56) and L-PE (n = 19) diagnosed according to The American College of Obstetricians and Gynecologists criteria (13) . Control placentae were obtained from preterm control (PTC) (n = 43) and term control (TC) (n = 23) normotensive age-matched deliveries. Serum was obtained at delivery from E-PE (n = 10) and PTC (n = 10). Supplemental Table 1 summarizes clinical parameters of the female patient population.
Cell culture conditions
JEG3 choriocarcinoma cells (RRID: CVCL_0363; ATCC, Manassas, VA) were cultured in either hypoxic (3% O 2 , 5% CO 2 , 92% N 2 ) or normoxic (21% O 2 , 5% CO 2 , 74% N 2 ) conditions. Primary trophoblasts were isolated from term placentae as previously described (18 Antibodies, horseradish peroxidase substrates, and Western blotting
Western blotting was performed as previously described (6) . For details on procedures, reagents, and antibodies used, see Supplemental Materials.
Plasmid transfections
The JMJD6 WT plasmid (p6352 MSCV-CMV-CMV-Flag-HA-JMJD6) was obtained from Addgene [plasmid 31358 (19) ; Cambridge, MA]. Mutated JMJD6 constructs were generated using site-directed mutagenesis whereby histidine 187 was mutated to alanine (H187A) in combination with aspartic acid mutated to alanine (D189A). For details on plasmid transfections, see Supplemental Materials.
Histone isolations and "in vitro demethylation" reactions Total histones were isolated from primary trophoblasts or PE, PTC, and TC placentae using the EpiQuick Total Histone Extraction Kit (OP-0006; Epigentek, Farmingdale, NY). For enzyme studies, 20 mg of histone substrates was incubated with 25 to 100 ng of purified human recombinant JMJD6 enzyme (BPS Bioscience, San Diego, CA) as optimized for each model. For details, see Supplemental Materials.
Iron and formaldehyde detection assays
Intracellular iron content in placental tissue was measured using a commercially available Iron Assay Kit (catalog ab83366; Abcam, Cambridge, UK). JMJD6 histone demethylase activity was determined using a Histone Demethylase Fluorescence Activity kit (catalog K010-F1; Arbor Assays, MI), according to the manufacturer's instructions. For details on procedures, see Supplemental Materials.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) of JMJD6, H3R2me2, and H4R3me2 in E-PE and PTC placentae was performed using the AbCam High-Sensitivity ChIP Kit (ab185913), according to the manufacturer's instructions. For details on procedures, see Supplemental Materials.
RNA isolation and qPCR
Total RNA was isolated from JEG3 cells, primary trophoblasts, and placental tissue using TRIzol reagent (Invitrogen, Carlsbad, CA). In total, 1 mg total RNA was reverse transcribed (Invitrogen), and the complementary DNA was used to perform real-time qPCR analysis of human and mouse JMJD6, VHL, and 18S (TaqMan Assays-on-Demand; Applied Biosystems, Foster City, CA) in TaqMan Universal PCR Master Mix (Applied Biosystems). Data were analyzed as described in Livak and Schmittgen (20) .
Statistical analysis
Statistical analyses were performed using GraphPad Prism 7.0 software (RRID: SCR_0027968; GraphPad Software, San Diego, CA). While comparing two groups, an unpaired Student t test was used. While comparing three or more groups, a oneway analysis of variance followed by a Tukey posttest was used. Data are expressed as mean 6 standard error of the mean.
Results
VHL gene and protein levels are reduced in early-onset preeclampsia VHL messenger RNA (mRNA) was significantly decreased in E-PE placentae relative to PTC, whereas no changes were observed in L-PE compared with TC placentae (Fig. 1a) . Accordingly, pVHL levels were also significantly reduced in E-PE (Fig. 1b) . Corroborating this, we found a marked reduction in HIF1A ubiquitination in E-PE, contributing to elevated HIF1A protein content (Supplemental Fig. 1 ). Given the significance of placental hypoxia in E-PE, we investigated whether changes in oxygen affected VHL gene expression. qPCR analysis demonstrated significant downregulation of VHL mRNA in JEG3 cells exposed to low oxygen (3% O 2 ) ( 
The JmjC domain of JMJD6 regulates VHL gene expression in an oxygen-dependent manner
In light of evidence implicating JMJD6 in histone demethylation, we examined whether JMJD6 regulated VHL gene expression and, if so, whether this was dependent on oxygen. qPCR analysis of JEG3 cells exposed to 3% and 21% O 2 and transfected with either WT JMJD6 construct or pMSCV empty vector (control) revealed that in ambient air, VHL mRNA levels were significantly upregulated upon JMJD6 overexpression, but they remained unchanged following JMJD6 overexpression at 3% O 2 ( Fig. 2a and 2b, left panel) . Given the central role of the JmjC catalytic domain in executing JMJD6 enzyme function (8), we generated JMJD6 constructs carrying two point mutations in this domain (Mut JMJD6), abolishing its iron-binding capacity and, hence, its demethylase activity (Fig. 2a) . Upon transfection of WT JMJD6 in JEG3 cells exposed to 21% O 2 , we observed a significant increase in VHL mRNA relative to empty vector control, whereas transfection with Mut JMJD6 failed to upregulate VHL mRNA (Fig. 2b, right panel) . Western blotting for VHL revealed a similar pattern, whereby overexpression of WT JMJD6 significantly induced pVHL in 21% O 2 , whereas overexpression of the mutant did not show this effect (Supplemental Fig. 2 ). Next, we directly quantified JMJD6 demethylase activity as a function of oxygen and found that upon incubation of bulk histones with recombinant JMJD6 enzyme in 3%, 8%, and 21% O 2 , JMJD6 activity was minimal at 3% O 2 and increased at 8% and 21% O 2 (Fig. 2c, left panel) . Furthermore, JMJD6 activity was markedly reduced in the absence of Fe 2+ and in the presence of the iron chelator, desferroxamine, whereas Fe 2+ addition restored activity even in low oxygen (Fig. 2d) . Western blotting for the two JMJD6 histone targets-namely, H3R2me2s and H4R3me2s-revealed a gradient preference for demethylation of the H4R3me2s mark in 8% and 21% O 2 (Supplemental Fig. 3a ).
JMJD6 demethylase activity is compromised in E-PE-derived histones
We next conducted an in vitro demethylation reaction using histones extracted from E-PE and PTC placentae and found reduced JMJD6 histone demethylase activity in E-PE-derived histones compared with PTC, suggesting compromised JMJD6 function (Fig. 3a) . In contrast, no changes in JMJD6 activity were observed in L-PE relative to TC (Fig. 3a) . The reduction in JMJD6 demethylase activity was accompanied by significantly increased content of both H3R2me2s and H4R3me2s marks in E-PE relative to PTC (Fig. 3b) . Confirming the relevance of hypoxia, both JMJD6 histone targets were elevated in primary trophoblasts cultured at 3% relative to normoxic 8% O 2 (Supplemental Fig. 3b) . JMJD6, H3R2me2s, and H4R3me2s levels in placentae from chronic essential hypertension did not vary in abundance relative to TC (Supplemental Fig. 3c) . Notably, Western blotting for H3R2me2s and H4R3me2s in histones from PTC placentae showed a significant decrease in both marks upon addition of JMJD6 enzyme (Fig. 3c, left panels) , whereas no differences were observed upon enzyme addition in histones from E-PE placentae (Fig. 3c, right panels) .
VHL gene is subject to modification by JMJD6-dependent histone arginine demethylation
To study the impact of JMJD6-mediated histone demethylation on VHL gene transcription, we performed ChIP of H3R2me2s and H4R3me2s in E-PE and PTC placentae and examined VHL gene expression using primers spanning various promoter regions (Fig. 4a and Supplemental Table 2 ). We found that (i) H4R3me2s was significantly enriched across three regions of the VHL promoter in PTC placentae, whereas it was minimal in E-PE (Fig. 4b) , and (ii) H4R3me2s-VHL and H3R2me2s-VHL associations were downregulated in E-PE in two regions upstream of the VHL minimal promoter (Fig.  4c) . No alterations were found in H4R3me2s-VHL or H3R2me2s-VHL binding in the minimal promoter (Supplemental Fig. 4a ). ChIP of JMJD6 in E-PE and PTC placentae followed by qPCR for VHL across regions revealed that JMJD6 associates to VHL in vivo, and its association to VHL is markedly reduced across the VHL minimal promoter in E-PE (Fig. 4d) . Concomitant with lack of H3R2me2s and H4R3me2 enrichment at an exon, we did not detect JMJD6 occupancy in this region (Supplemental Fig. 4b ).
JMJD6 histone demethylase function is disrupted in a murine model of pharmacological hypoxia during pregnancy
Disruptions in the oxygen-sensing machinery are at the core of E-PE (16 One-way analysis of variance and Tukey posttest; *P , 0.05, 21% empty vector (EV) vs 21% overexpression (OE); **P , 0.01, 21% EV vs 3% EV, n = 3. (b, right panel) qPCR for VHL in JEG3 cells transfected with either WT or Mut JMJD6 in 21% O 2 relative to EV. Unpaired Student t test; *P , 0.05, ***P , 0.001, n = 3. (c) JMJD6 demethylase activity in bulk histones at 3%, 8%, or 21% O 2 . One-way analysis of variance and Tukey posttest; *P , 0.05, **P , 0.01, n = 3. (d) JMJD6 histone demethylase activity in bulk histones exposed to varying oxygen tension (3%, 8%, or 21% O 2 ) in the presence and absence of iron (50 mM), the iron chelator desferroxamine (100 mM), or supplemented with excess iron (+15 mM). NLS, nuclear localization signal; ns, not significant. doi: 10.1210/jc.2017-02197 https://academic.oup.com/jcemFG-4592 treatment resulted in significantly decreased placental and fetal weights compared with DMSO-treated controls (Fig. 5a ). Hematoxylin and eosin staining of placental sections revealed visible disruptions in placental architecture, particularly within the labyrinthine zone in the FG-4592 mice (Fig. 5b, left panels) , including its compaction and decreased branching and vascularization, as evident from staining for the vascularity marker, CD34 (Fig. 5b, right panels) . In line with our E-PE data, VHL protein and mRNA were decreased in the FG-4592 placentae (Fig. 5c) , accompanied by elevated JMJD6 protein levels (Fig. 5d) . Western blotting Western blots of H3R2me2s and H4R3me2s in E-PE and PTC histones and associated densitometry. Unpaired Student t tests; *P , 0.05, n = 9 (PTC), n = 11 (E-PE). (c) Western blots and associated densitometry of H3R2me2s and H4R3me2s in histones isolated from PTC and E-PE placentae upon incubation with 25 ng JMJD6 enzyme at 21% O 2 . Unpaired Student t test; *P , 0.05, n = 5. Data represented as mean 6 standard error of the mean. ns, not significant. revealed increased abundance of H3R2me2s and H4R3me2s in histones from placentae of FG-4592-treated mice relative to DMSO controls (Supplemental Fig. 3d ).
Iron supplementation can rescue JMJD6 histone demethylase activity in preeclamptic placentae Women with PE have significantly elevated serum iron levels (15) . In line with this, we detected increased expression of the ferroxidase enzyme, ceruloplasmin (CP; converts Fe 2+ to Fe 3+ ), in sera and placentae from E-PE pregnancies (Fig. 6a) . This was accompanied by significantly reduced total iron and Fe 2+ content in E-PE tissue, relative to PTC (Fig. 6b) . Confirming the central role of Fe 2+ in mediating JMJD6 function, supplementation of E-PE and PTC-derived histones with excess Fe 2+ significantly increased JMJD6 histone demethylase activity not only in PTC but also, notably, in E-PE (Fig. 6c) , whereas addition of desferroxamine abrogated demethylase activity. Accordingly, H3R2me2s and H4R3me2s levels were decreased upon Fe 2+ supplementation of PTC and E-PE histones (Fig. 6d) .
In line with our human data, incubation of histones from DMSO and FG-4592-treated mice placentae with JMJD6 enzyme revealed that JMJD6 demethylase activity is compromised upon FG-4592 treatment, and addition of excess Fe 2+ rescues loss of JMJD6 histone demethylase activity in FG-4592-treated placentae (Fig. 6e) . Furthermore, we found elevated placental levels of CP in mouse placentae following FG-4592 treatment (Fig. 6f) .
Discussion
To our knowledge, this study presents new evidence on epigenetic regulation of VHL, a multifaceted tumor suppressor protein that is critically required for proper placental development. We report that the oxygen sensor, JMJD6, contributes to VHL gene regulation in the human placenta via targeted histone arginine demethylation. Importantly, in E-PE but not L-PE, JMJD6 histone demethylase function is impaired due to hypoxia-iron imbalance, contributing to VHL downregulation in this serious disorder of pregnancy. Hypoxia is a powerful inducer of the molecular machinery underlying epigenetic events (23) by upregulating the expression of several JmjC domain proteins while attenuating their activity. Accordingly, we observed that JMJD6, a protein we have previously identified as being upregulated in hypoxia (6), exhibits histone demethylase activity in the placenta in an oxygen-dependent manner. Although some studies have failed to detect evidence of histone arginine demethylase activity for JMJD6, others have corroborated it in their respective models (24, 25 ).
In the current study, we detected an oxygen gradient preference for demethylation of H4R3me2s but not H3R2me2s at 8% O 2 , likely reflecting physiological differences in enzyme sensitivity to specific histone marks. Therefore, identifying the physiological oxygen concentrations that modulate JMJD6 activity is critical for understanding epigenetic consequences in the human placenta, a tissue that uniquely adapts and responds to changes in oxygen tension throughout pregnancy.
Compelling evidence indicates that E-PE is a pathology of placental origin, and although it constitutes a subset of all preeclamptic cases, it is associated with higher adverse maternal and perinatal outcomes (26, 27) . L-PE, on the other hand, is believed to stem from increased susceptibility of the maternal endothelium to proinflammatory factors, resulting in a generalized abnormal maternal vascular response (28) . Of note, chronic uteroplacental ischemia and associated hypoxia due to increased resistance to blood flow was found to be strongly correlated with E-PE (29) . At the molecular level, markers of hypoxia, reactive oxygen species, and markers of DNA damage are reported to be elevated in E-PE compared with L-PE placentae (30) . In agreement with this, we have previously demonstrated striking changes in oxygen sensor profiles between E-PE and L-PE, reflecting the persistent hypoxic environment (17) . Likewise, the in vitro demethylation reactions conducted in the current study reveal that JMJD6 activity is compromised only in histones derived from E-PE placentae even at equivalent amounts of enzyme, cofactors, and oxygen availability as L-PE and their normotensive counterparts. This suggests that the E-PE hypoxic environment in vivo alters the histone arginine methylation signature, thereby reducing their capacity to be demethylated in the presence of the exogenous JMJD6 enzyme. Moreover, although E-PE histones are sensitive to Fe 2+ -assisted JMJD6 demethylation, they fail to respond below threshold levels of Fe 2+ availability. Thus, chronic placental hypoxia, accompanied by decreased Fe 2+ content/availability, contributes to reduced JMJD6 activity, resulting in an altered histone methylation landscape and VHL gene repression in E-PE. Interestingly, our observation of decreased pVHL in E-PE is seemingly in contradiction to a study (31) that found no changes in VHL protein abundance in PE; this discrepancy is possibly due to their use of L-PE placentae with an average gestational age of .35 weeks. This further highlights the unique molecular signature of E-PE-vs L-PE and the need to distinguish the two pathologies. The literature on VHL in pregnancy remains sparse to date. Work on its importance in placentation is restricted to Vhl 2/2 mice that exhibit in utero mortality due to placental failure (3). Impaired vessel formation, syncytiotrophoblast cell development, and resultant placental necrosis were deemed as the primary events underlying embryonic death in these mice. This underscores the importance of VHL in mediating placental vasculogenesis and is in agreement with our data on VHL gene and protein downregulation in a pharmacological model of hypoxia accompanied by vascular disruptions in the placental labyrinthine layer. Histone modifications and DNA methylation are epigenetic events that often work in concert to influence gene expression. A seminal study found that in ccRCC tumors, hypermethylation of a CpG island in the first exon of VHL was largely responsible for gene inactivation and loss of function (32) . Other studies detected hypermethylation of CpG islands specific to the VHL promoter in a subset of patients with ccRCC (33) . In the human placenta, there is a strong body of work showing that E-PE is associated with distinct DNA methylation patterns at several placental gene loci (34) (35) (36) that differ from that of L-PE. On the other hand, few studies have examined histone posttranslational modifications and their significance in PE. Herein, we found that VHL association to H3R2me2s and H4R3me2s is strikingly decreased in E-PE owing to changes in oxygen tension that ultimately dictate JMJD6 enzyme activity. Moreover, although there is an overall increase in the abundance of H3R2me2s and H4R3me2s in E-PE, their enrichment across the VHL promoter is markedly reduced. Genome-wide studies indicate that H3R2me2s is enriched at highly active genes, whereas H4R3me2s is enriched at "moderately" active genes (37) . Hence, despite an increase in the overall protein abundance of the two histone marks in E-PE, their markedly reduced association to the VHL promoter correlates with gene repression. Besides alterations in arginine methylation status, the ChIP studies in E-PE and PTC placentae also suggest that JMJD6 may directly contribute to VHL gene regulation by binding to the VHL minimal promoter. Given the abundance of transcription factor binding sites and other regulatory elements within this region, this has important implications for VHL transcriptional regulation.
The importance of Fe 2+ in modulating JMJD6 histone demethylase activity is exemplified by our in vitro demethylation experiments conducted in bulk histones and those derived from E-PE and FG-4592-treated mice placentae. Ferrous iron is highly reactive, and so it is critical that intracellular iron levels are tightly controlled. The ferroxidase enzyme CP is used by many tissues to facilitate iron export (38) , playing a critical role in iron metabolism. Despite CP being primarily present in the plasma, other studies have proven its existence in syncytiotrophoblasts of the placenta, highlighting a role for CP in placental iron export (39) . In line with our finding of elevated CP upon FG-4592 treatment (mimicking hypoxia), CP is known to be transcriptionally upregulated by hypoxia via HIF1A activation (40) . Consistent with reports in the literature (41, 42) , our study found significantly elevated CP in both sera and placentae of preeclamptic women. Interestingly, CP ferroxidase activity is also reportedly enhanced in PE (43) , lending credence to our hypothesis of enhanced Fe 2+ outflux from preeclamptic trophoblast cells. This is further supported by our finding that E-PE placentae have significantly lower total and ferrous iron content, and this has implications not only for JMJD6 function but also for the activity of numerous Fe 2+ -dependent enzymes that orchestrate diverse cellular processes.
Can alterations in iron metabolism be ameliorated in PE? From a clinical standpoint, there is no evidence that dietary iron supplementation improves pregnancy outcomes. This is likely because increasing iron intake alone does not ensure optimal iron absorption. Interestingly, our data also suggest that addition of excess Fe 2+ can functionally "rescue" JMJD6 histone demethylase activity even in low oxygen, as demonstrated in bulk histones and E-PE-derived histones. This suggests that irrespective of hypoxia, disrupted iron homeostasis in E-PE is potentially an important clinical target.
In conclusion, the findings reported herein shed new light on VHL epigenetic regulation in the human placenta (see putative model in Supplemental Fig. 5 ), an event that is disrupted in E-PE. Taken together, this work provides novel insights on oxygen sensing in this pathology while raising new questions on its pathogenesis and providing novel therapeutic targets for further investigation.
